General information

Images information

Fields information

Foti C, Cisari C, Carda S, Giordan N, Rocco A, Frizziero A, Della Bella G. A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate (MW 1500-2000 KDa; Hyalubrix®) in synovial joints with osteoarthritis European journal of psychical and rehabilitation medicine vol 47 2011
Griffin MR, Yared A, Ray WA. Non steroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000
Hayes Hyaluronic Acid/Viscosupplementation A Health Technology Assessment Prepared for Washington State Health Care Authority FINAL REPORT – October 14, 2013
Henry D. Non-steroidal anti-inflammatory drugs and the risk of development of congestive cardiacfailure and functional renal impairment. Proceedings of the international conference on inflammopharmacology, San Francisco, 1997.
Karlsson J, Sjögren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicenter study. Rheumatology 2002
Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998
Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis:findings from clinical practice in Canada. J Rheumatol 1996
Marshall KW. Viscosupplementation for osteoarthritis: current status, unresolved issues and future directions. J Rheumatol. 1998
Migliore A. Hip viscosupplementation under ultra-sound guidance riduces NSAID consumption in symptomatic hip osteoarthritis patients in a long follow-up. Data from italian registry 2011
Moore RA, Philips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999
National Center for Health Statistics: Prevalence of osteoarthritis in adults by age, sex, race and geographic area: United States 1960-62. Vital and Health Statistics no. 15, series 11 Washington, DC: Government Printing Office; 1966.
Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000
Schieb F. Intraartikular injizierte Hyaluronsaure bei Arthropathien. Arthritis Rheum 2003
Straube S, Tramer MR, Moore RA, Derry S, Mcquai HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 2009
Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non steroidal anti-inflammatory drugs for osteoarthritis of the hip (Cochrane review). In: The Cochrane library, issue 1. Oxford: Update Software, 2000
Yasui T, Akatsuka M, Tobetto K. Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes. Biomed Res 1992
Zhang W, Moskowitz RW, Nuki G, Abramsons S, Altman RD, Arden N, Bierma-Zeistra S, Brandt KD, Croft P, Doherty M, Dougades M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence- based expert consensus guidelines. Osteoarthritis Cartilage 2008;

Foti C, Cisari C, Carda S, Giordan N, Rocco A, Frizziero A, Della Bella G. A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate (MW 1500-2000 KDa; Hyalubrix®) in synovial joints with osteoarthritis European journal of psychical and rehabilitation medicine vol 47 2011
Griffin MR, Yared A, Ray WA. Non steroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000
Hayes Hyaluronic Acid/Viscosupplementation A Health Technology Assessment Prepared for Washington State Health Care Authority FINAL REPORT – October 14, 2013
Henry D. Non-steroidal anti-inflammatory drugs and the risk of development of congestive cardiacfailure and functional renal impairment. Proceedings of the international conference on inflammopharmacology, San Francisco, 1997.
Karlsson J, Sjögren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicenter study. Rheumatology 2002
Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998
Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis:findings from clinical practice in Canada. J Rheumatol 1996
Marshall KW. Viscosupplementation for osteoarthritis: current status, unresolved issues and future directions. J Rheumatol. 1998
Migliore A. Hip viscosupplementation under ultra-sound guidance riduces NSAID consumption in symptomatic hip osteoarthritis patients in a long follow-up. Data from italian registry 2011
Moore RA, Philips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999
National Center for Health Statistics: Prevalence of osteoarthritis in adults by age, sex, race and geographic area: United States 1960-62. Vital and Health Statistics no. 15, series 11 Washington, DC: Government Printing Office; 1966.
Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000
Schieb F. Intraartikular injizierte Hyaluronsaure bei Arthropathien. Arthritis Rheum 2003
Straube S, Tramer MR, Moore RA, Derry S, Mcquai HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 2009
Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non steroidal anti-inflammatory drugs for osteoarthritis of the hip (Cochrane review). In: The Cochrane library, issue 1. Oxford: Update Software, 2000
Yasui T, Akatsuka M, Tobetto K. Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes. Biomed Res 1992
Zhang W, Moskowitz RW, Nuki G, Abramsons S, Altman RD, Arden N, Bierma-Zeistra S, Brandt KD, Croft P, Doherty M, Dougades M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence- based expert consensus guidelines. Osteoarthritis Cartilage 2008;